Zoltan Sutto
Semmelweis University
13 Papers
55 Citations
Zoltan Sutto is an academic researcher from Semmelweis University. The author has contributed to research in topics: Lung transplantation & Medicine. The author has an hindex of 7, co-authored 11 publications. Previous affiliations of Zoltan Sutto include University of Miami.
Chat about Author
Papers
Soluble adenylyl cyclase is localized to cilia and contributes to ciliary beat frequency regulation via production of cAMP.
Andreas Schmid,Zoltan Sutto,Marie Christine Nlend,Gabor Horvath,Nathalie Schmid,Jochen Buck,Lonny R. Levin,Gregory E. Conner,Nevis Fregien,Matthias Salathe +9 more
TL;DR: CO2/HCO3 − increases indeed reversibly stimulate intracellular cAMP production by sAC in intact cells, and it contributes to the regulation of human airway CBF.
Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells
Gabor Horvath,Zoltan Sutto,Zoltan Sutto,Aliza Torbati,Gregory E. Conner,Matthias Salathe,Adam Wanner +6 more
TL;DR: Although human bronchial arterial SMC express OCT-1 and EMT, EMT is the predominant plasma membrane transporter for NE uptake, and this process can be inhibited by GSs, likely via a specific membrane binding site.
65
Decreased Soluble Adenylyl Cyclase Activity in Cystic Fibrosis Is Related to Defective Apical Bicarbonate Exchange and Affects Ciliary Beat Frequency Regulation
Andreas Schmid,Zoltan Sutto,Zoltan Sutto,Nathalie Schmid,Lisa Novak,Pedro I. Ivonnet,Gabor Horvath,Gabor Horvath,Gregory E. Conner,Nevis Fregien,Matthias Salathe +10 more
TL;DR: The results suggest that CBF regulation by sAC-produced cAMP could be impaired in CF, thereby possibly contributing to mucociliary dysfunction in this disease, at least during disease exacerbations when airway acidification is common.
54
Remdesivir in Solid Organ Recipients for COVID-19 Pneumonia
Dorottya Fesu,Anikó Bohács,Edit Hidvégi,Zsombor Matics,L. Polivka,Peter Horvath,Ibolya Czaller,Zoltan Sutto,Noémi Eszes,Krisztina Vincze,V. Muller +10 more
TL;DR: In this article , the authors evaluated the efficacy and safety of remdesivir (RDV) therapy in infected hospitalized SOT patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
9
Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment
L. Polivka,J. Gajdácsi,Levente Fazekas,Szilvia Szilágyi Sebők,Eniko Barczi,Edit Hidvégi,Zoltan Sutto,Elek Dinya,Pál Maurovich-Horvat,Attila Szabo,Béla Merkely,Veronika Müller +11 more
TL;DR: Hospitalized COVID-19 patients with 5-day RDV treatment had significantly lower 30- and 60-day all-cause mortality, despite their more severe clinical condition, and men and patients with multiple comorbidities, including COPD, profited the most fromRDV treatment in the long term.
8